Datopotamab deruxtecan with durvalumab adjuvant therapy for treating triple-negative breast cancer

Datopotamab deruxtecan in combination with durvalumab is in clinical development for the treatment of non-metastatic triple-negative breast cancer (TNBC), following neo-adjuvant therapy. Breast cancer is the growth of abnormal cells in the breast that divide uncontrollably to eventually form a tumour. Non-metastatic refers to cancer that has not spread beyond the primary site of origin, nor invaded distant organs or tissues. TNBC is a subtype of breast cancer that lacks hormone receptor expression. The risk factors for TNBC include a history of breast disease and radiation therapy, family history of TNBC, alcohol intake, smoking, exposure to carcinogenic chemicals, and the intake of processed food. Chemotherapy is the main form of treatment for patients with TNBC; however, the effectiveness of chemotherapy for TNBC remains limited.